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7EDITORIAL Open AccessThe additional facet of immunoscore:
immunoprofiling as a possible predictive tool for
cancer treatment
Paolo A Ascierto1*, Mariaelena Capone1, Walter J Urba2, Carlo B Bifulco2, Gerardo Botti1, Alessandro Lugli3,
Francesco M Marincola4, Gennaro Ciliberto1, Jérôme Galon5,6,7 and Bernard A Fox2,8Abstract
Recent investigations of the tumor microenvironment have shown that many tumors are infiltrated by
inflammatory and lymphocytic cells. Increasing evidence suggests that the number, type and location of these
tumor-infiltrating lymphocytes in primary tumors has prognostic value, and this has led to the development of an
‘immunoscore. As well as providing useful prognostic information, the immunoscore concept also has the potential
to help predict response to treatment, thereby improving decision- making with regard to choice of therapy. This
predictive aspect of the tumor microenvironment forms the basis for the concept of immunoprofiling, which can
be described as ‘using an individual’s immune system signature (or profile) to predict that patient’s response to
therapy’ The immunoprofile of an individual can be genetically determined or tumor-induced (and therefore
dynamic). Ipilimumab is the first in a series of immunomodulating antibodies and has been shown to be associated
with improved overall survival in patients with advanced melanoma. Other immunotherapies in development
include anti-programmed death 1 protein (nivolumab), anti-PD-ligand 1, anti-CD137 (urelumab), and anti-OX40.
Biomarkers that can be used as predictive factors for these treatments have not yet been clinically validated.
However, there is already evidence that the tumor microenvironment can have a predictive role, with clinical
activity of ipilimumab related to high baseline expression of the immune-related genes FoxP3 and indoleamine 2,3-
dioxygenase and an increase in tumor-infiltrating lymphocytes. These biomarkers could represent the first potential
proposal for an immunoprofiling panel in patients for whom anti-CTLA-4 therapy is being considered, although
prospective data are required. In conclusion, the evaluation of systemic and local immunological biomarkers could
offer useful prognostic information and facilitate clinical decision making. The challenge will be to identify the
individual immunoprofile of each patient and the consequent choice of optimal therapy or combination of
therapies to be used.
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IpilimumabRecent investigations of the tumour microenvironment
(TME) have shown that many tumors are heavily infil-
trated by a complex repertoire of inflammatory and
lymphoid cells. Immune cells appear as dense infiltrates
in the center of the tumoral zone, at the invasive margin
of the tumor, and as lymphoid islets adjacent to the
tumor. Increasing evidence supports the hypothesis that* Correspondence: paolo.ascierto@gmail.com
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reproduction in any medium, provided the orthe number, type and location of tumor-infiltrating lym-
phocytes (TILs) in primary tumors have prognostic
value, and this has led to the development of the new
concept of “immunoscore”, e.g. a quantifiable measure
of the infiltrate that can potentially be used as a prog-
nostic factor [1]. This immunoscore is primarily based
on the density of two lymphocyte populations, cytotoxic
(CD8) and memory (CD45RO) T cells (CD3/CD45RO,
CD3/CD8 or CD8/CD45RO), both in the center and the
invasive margins of tumors [2-4].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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proof of principle during research development of the
immunoscore, the relevance of the CD8 + (CD45RO or
CD3) phenotype has also been shown in other tumor
types, with high densities of cytotoxic and memory T
cells associated with longer disease-free (after surgical
resection of the primary tumor) and/or overall survival
in several cancer types [5]. However, the nature of TILs
is heterogeneous between tumors and so, in order to fur-
ther validate the concept of the immunoscore as a prog-
nostic factor, this needs to be characterized in other
tumor types such as melanoma, renal cell, prostate,
ovarian and breast cancer. Studies have already begun to
investigate the relationship between Immunoscore-like
markers and prognosis in cancers other than colorectal.
For example, a retrospective study involving 102 women
with a histologically confirmed diagnosis of early inva-
sive breast cancer recently reported that an increased
CD68 count and CD68/(CD3 +CD20) ratio at the invasive
front of the carcinoma was significantly associated with
occurrence of distant metastasis [6]. Further, the reverse
phenotype (CD68low/CD4low/CD8high) was identified as an
independent prognostic indicator of breast cancer survival
(p < 0.001) in a retrospective study of 677 patients [7].
As well as providing useful prognostic information,
the immunoscore concept also has the potential to help
predict response to treatment, thereby helping improve
therapeutic decisions. This predictive aspect of the quan-
tity, quality, and distribution of the immunologic TME
forms the basis for the concept of immunoprofiling, which
can be defined as “using an individual’s immune system
signature to predict the response to therapy” (see Table 1).
The immunoprofile of an individual can be genetically de-
termined or tumor-induced (and therefore dynamic). For
example, it has previously been reported that someTable 1 Differences between immunoscore and immunoprofil
Immunosc
Prognostic/Pred
Number of immune markers 2-4
Immunoscore markers CD3/CD8
Immunoscore-like markers CD3/CD8/CD20
CD3/CD8/CD
CD4/CD8/C
CD3/CD8/CD20, C
CD8/FoxP
CD8/IL17
(others)
Possible application • Staging in colorectal cancer (already teste
• Staging in Melanoma, Breast cancer, Ovar
Pancreatic cancer, Head & Neck cancer (toregional lymph nodes close to primary melanomas and
breast cancers are immune-suppressed and that the de-
gree of immune suppression is directly correlated with the
closeness of the node to the tumor [8]. It has also been
demonstrated that interdigitating dendritic cells are re-
duced and lack the complex dendrites that characterize
active antigen presentation in nodes proximal to the
tumor or partly replaced by tumor (e.g. sentinel lymph
nodes). This could suggest nodal immune suppression
due to tumor influence, mediated in part by melanoma-
derived materials [9].
With the advent of immunotherapies, the predictive
role of immunoprofiling will become a fundamental tool
for patients’ management. Ipilimumab, a monoclonal
antibody which antagonizes cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4), is the first in a series of
immunomodulating antibodies to become available.
Tumors typically develop multiple mechanisms to evade
the endogenous immune response, including ‘immune
checkpoints’ that can terminate immune responses after
antigen activation. Immune checkpoint inhibitors, such
as ipilimumab, have thus been a key target in the devel-
opment of immunotherapeutic approaches for cancer.
Treatment with ipilimumab has been shown to be associ-
ated with improved overall survival in patients with ad-
vanced melanoma [10]. Other immunotherapies currently
being evaluated in clinical trials include anti-programmed
death 1 (PD1) protein (nivolumab), anti-PD-ligand 1 (PD-
L1) and anti-CD137 (urelumab), and anti-OX40 [10-13].
Biomarkers that can be used as predictive factors for
ipilimumab treatment have not yet been identified. How-
ever, there is already evidence that characteristic TMEs
can have a predictive role. A retrospective study in pa-
tients treated with ipilimumab suggested that clinical
activity was related to high expression of the immune-ing
ore Immunoprofiling
ictive(?) Prognostic/Predictive(?)
1 – Several
/FoxP3 Immune gene signatures
45RO Multiplex assays
D68 CD137, Galectin1, LAG-3, OX40, PD-
D3/GZMB
3
d) • Prognostic assay
ian cancer, NSCLC, Prostate cancer,
be defined).
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(IDO) at baseline and an increase from baseline in TILs
(at week 4) in tumor biopsies [14]. These biomarkers
could represent the first potential proposal for an
immunoprofiling panel in patients for whom anti-CTLA-4
therapy is being considered. However, these findings need
to be confirmed in a large, prospective clinical trial. Simi-
larly, in a recent study of the new anti-PD-1 agent
nivolumab, preliminary findings suggested that the im-
munosuppressive PD-1 ligand, PD-L1 (B7-H1), could be a
possible predictive biomarker of therapeutic response. In a
subset of patients (n = 42) with various cancers, 36% with
positive PD-L1 expression on the surface of tumor cells in
pre-treatment tumor specimens had an objective response
to treatment with anti-PD-1, while none of the patients
with PD-L1-negative tumors had an objective response
[15]. Again, prospective studies are needed to define
the potential role of this biomarker. Other cells such as
myeloid derived suppressor cells (MDSC) can be
detected as infiltrating components of primary or meta-
static lesions, suggesting a potential involvement in mel-
anoma progression. Moreover, this kind of cells could
have a role in predicting the response to ipilimumab [16].
This approach could form the basis for the evaluation
of other immunomodulating antibody targets as possible
predictive markers. Anti-PD-L1, anti-Lag3, anti-KIR,
anti-TIM-3, anti-GITR, anti-OX40 and anti-CD137 rep-
resent the future of immunotherapy and it may be that
assessment of the relevant markers can help define the
individual immune system profile. This can then be used
to help guide treatment choices with the different im-
munotherapies, used either alone or in combination.
Effective Immunoprofiling will not only consider the sur-
face receptors of immune system cells, but also the pres-
ence of ectopic immune structures such as the tumor-
localized ectopic lymph node-like structures (TL-ELNs)
[17]. Recently, it was demonstrated that a 12-chemokine
gene expression signature (CCL2, CCL3, CCL4, CCL5,
CCL8, CCL18, CCL19, CCL21, CXCL9, CXCL10, CXCL11,
and CXCL13) is strongly associated with the presence of
TL-ELNs, and with a better patient outcome in colorectal
cancer and melanoma [18].
In conclusion, increasing evidence supports the view
that cancer development is strongly influenced by the
host immune system. The evaluation of systemic and
local immunological biomarkers could offer useful prognos-
tic information and facilitate clinical decision making about
the need for specific therapies, and the ‘immunoscore’
concept is quickly gaining momentum with additional
trials, research activity, and retrospective validations.
More patient-specific immunoprofiling represents yet
another step toward personalized medicine, incorporat-
ing tests that inform clinicians and patients toward
clear decision-making.Competing interest
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